Myomo (MYO) Projected to Post Earnings on Monday

Myomo (NYSEAMERICAN:MYO) is projected to issue its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $10.4030 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Myomo Trading Down 4.8%

NYSEAMERICAN:MYO opened at $0.80 on Friday. Myomo has a one year low of $0.64 and a one year high of $6.30. The firm has a market capitalization of $30.75 million, a price-to-earnings ratio of -2.76 and a beta of 1.17. The business has a fifty day moving average price of $0.87 and a 200-day moving average price of $0.93. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.49 and a quick ratio of 2.10.

Institutional Investors Weigh In On Myomo

Several hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new position in shares of Myomo in the 4th quarter valued at $148,000. AQR Capital Management LLC lifted its position in Myomo by 47.8% in the fourth quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock valued at $395,000 after acquiring an additional 140,427 shares during the last quarter. State Street Corp boosted its stake in Myomo by 5.1% in the fourth quarter. State Street Corp now owns 399,853 shares of the company’s stock valued at $364,000 after acquiring an additional 19,563 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Myomo by 103.1% in the fourth quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock valued at $35,000 after acquiring an additional 19,646 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Myomo during the fourth quarter worth about $64,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price target on Myomo from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, Myomo currently has a consensus rating of “Buy” and a consensus price target of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.